Nintedanib (Ofev)

Small molecule

Also known as BIBF 1120

Approvedregulatory verdict

Evidence outlook

Approved: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (4)
US
  • Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype OFEV is indicated for the treatment of adults with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype [see Clinical Studies (14.2) ] .Outside this platform's coverage
  • Systemic Sclerosis-Associated Interstitial Lung Disease OFEV is indicated to slow the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Product first approved 2014FDA label
JP
  • Treatment of idiopathic pulmonary fibrosis
Product first approved 2015PMDA
EU
  • Ofev is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Product first approved 2015EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (20)
Idiopathic Pulmonary Fibrosis
NCT01619085 · Boehringer Ingelheim
2012-06-06 – 2021-02-01 · Idiopathic Pulmonary Fibrosis
What this study did
NCT02802345 · Boehringer Ingelheim
2016-06-30 – 2018-04-13 · Idiopathic Pulmonary Fibrosis
What this study did
NCT01979952 · Boehringer Ingelheim
2013-11-26 – 2016-10-27 · Idiopathic Pulmonary Fibrosis
What this study did
Systemic Sclerosis
NCT07335562 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2027-02-03 – 2030-11-11 · Systemic Sclerosis
What this study did
NCT06297096 · National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
2025-07-01 – 2028-03-30 · Systemic Sclerosis, Interstitial Lung Disease
What this study did
Other / comorbidity
NCT07162961 · Sun Yat-sen University
2025-09-01 – 2027-06-30 · Adenomyosis of Uterus
What this study did
NCT05285982 · Boehringer Ingelheim
2022-04-06 – 2025-08-13 · Lung Diseases, Interstitial
What this study did
NCT03283007 · Assistance Publique - Hôpitaux de Paris
2019-10-30 – 2025-03-30 · Lung-transplant Recipients
What this study did
NCT05067517 · West Virginia University
2021-11 – 2024-07 · Progressive Fibrosing Interstitial Lung Disease
What this study did
NCT04541680 · Assistance Publique - Hôpitaux de Paris
2020-10-29 – 2024-07 · SARS-Cov-2 Induced Pulmonary Fibrosis
What this study did
NCT05065190 · Boehringer Ingelheim
2021-11-25 – 2024-05-07 · Lung Diseases, Interstitial
What this study did
NCT03313180 · Boehringer Ingelheim
2017-11-27 – 2023-01-25 · Lung Diseases, Interstitial
What this study did
NCT03820726 · Boehringer Ingelheim
2019-04-16 – 2022-08-30 · Lung Diseases, Interstitial
What this study did
NCT04093024 · Boehringer Ingelheim
2019-12-03 – 2022-05-24 · Lung Diseases, Interstitial
What this study did
NCT02999178 · Boehringer Ingelheim
2017-01-17 – 2019-08-12 · Lung Diseases, Interstitial
What this study did
NCT01015118 · Boehringer Ingelheim
2009-11-17 – 2016-09-15 · Ovarian Neoplasms, Peritoneal Neoplasms
What this study did
NCT02149108 · Boehringer Ingelheim
2014-09-25 – 2016-08-25 · Colorectal Neoplasms
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT05635071 · Sixth Affiliated Hospital, Sun Yat-sen University
2023-12-01 – 2024-12-30 · Uterine Adhesions
What this study did
NCT01907100 · Boehringer Ingelheim
2013-09-19 – 2018-08-31 · Mesothelioma
What this study did
Phase 2 (49)
Idiopathic Pulmonary Fibrosis
NCT07583589 · First Affiliated Hospital of Wenzhou Medical University
2026-05-12 – 2027-06-01 · Idiopathic Pulmonary Fibrosis (IPF)
What this study did
NCT03562416 · Temple University
2019-07-05 – 2021-12-21 · Idiopathic Pulmonary Fibrosis, Lung Transplant; Complications
What this study did
NCT01170065 · Boehringer Ingelheim
2010-06-25 – 2016-09-26 · Pulmonary Fibrosis
What this study did
NCT01136174 · Boehringer Ingelheim
2010-05 – 2011-03 · Idiopathic Pulmonary Fibrosis
What this study did
Other / comorbidity
NCT06643091 · Assistance Publique - Hôpitaux de Paris
2024-11-01 – 2030-09-01 · Castleman Disease
What this study did
NCT04976036 · Dr. Romain Lazor
2022-05-05 – 2026-12 · Telangiectasia, Hereditary Hemorrhagic
What this study did
NCT03805477 · University Hospital, Basel, Switzerland
2019-03-20 – 2026-07-29 · Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans (BO)
What this study did
NCT04161014 · Holdsworth House Medical Practice
2020-10-09 – 2025-02 · Pneumoconiosis Coal, Asbestosis, Silicosis
What this study did
NCT02496585 · Memorial Sloan Kettering Cancer Center
2015-07-08 – 2024-04-12 · Lung Cancer, Lung Metastases
What this study did
NCT02863055 · European Organisation for Research and Treatment of Cancer - EORTC
2018-02-04 – 2024-01-10 · Malignant Pleural Mesothelioma
What this study did
NCT02009579 · Belgian Gynaecological Oncology Group
2014-03 – 2023-10 · Uterine Cervical Neoplasms
What this study did
NCT03954782 · Hospices Civils de Lyon
2020-06-22 – 2023-02-24 · Telangiectasia, Hereditary Hemorrhagic, Rendu Osler Disease
What this study did
NCT02399215 · Roswell Park Cancer Institute
2015-05-15 – 2022-08-31 · Carcinoid Tumor, Metastatic Carcinoid Tumor, Neuroendocrine Neoplasm
What this study did
NCT03292250 · Seoul National University Hospital
2017-09-10 – 2022-03-10 · HNSCC, Head and Neck Neoplasms
What this study did
NCT03062943 · IRCCS Multimedica
2016-12-06 – 2021-12 · Lymphangioleiomyomatosis
What this study did
NCT02730416 · Nordic Society of Gynaecological Oncology - Clinical Trials Unit
2016-12-12 – 2021-11-25 · Endometrial Cancer
What this study did
NCT02808247 · European Organisation for Research and Treatment of Cancer - EORTC
2017-07-07 – 2021-04-14 · Sarcoma, Soft Tissue
What this study did
NCT02665143 · Yale University
2016-07-21 – 2021-03-30 · Relapsed/Refractory Acute Myeloid Leukemia
What this study did
NCT02866370 · NHS Greater Glasgow and Clyde
2015-04 – 2021-03 · Ovarian Clear Cell Carcinoma, Endometrial Clear Cell Carcinoma
What this study did
NCT04338802 · Huilan Zhang
2020-04-02 – 2020-08-01 · COVID-19, Nintedanib, Safety, Effect of Drugs
What this study did
NCT01024920 · Boehringer Ingelheim
2009-12-16 – 2020-06-19 · Carcinoma, Renal Cell
What this study did
NCT02234596 · Memorial Sloan Kettering Cancer Center
2014-09-04 – 2020-04-22 · Esophagogastric Adenocarcinoma
What this study did
NCT03287947 · Wake Forest University Health Sciences
2017-11-10 – 2019-10-27 · Appendix Cancer
What this study did
NCT01788982 · European Organisation for Research and Treatment of Cancer - EORTC
2014-05 – 2019-08-28 · Medullary Thyroid Cancer (MTC), Differentiated Thyroid Cancer (DTC)
What this study did
NCT02452463 · Roswell Park Cancer Institute
2015-06-29 – 2019-06-10 · Lung Non-Squamous Non-Small Cell Carcinoma, Radiation-Induced Pneumonitis, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT02389764 · M.D. Anderson Cancer Center
2015-06-22 – 2019-06-08 · Breast Cancer
What this study did
NCT02856867 · European Organisation for Research and Treatment of Cancer - EORTC
2016-12 – 2019-06 · Esophagogastric Adenocarcinoma, Metastatic Disease, No Previous Chemotherapy for Metastatic Esophagogastric Cancer
What this study did
NCT02568449 · Barbara Ann Karmanos Cancer Institute
2016-03-15 – 2018-06-26 · Recurrent Pleural Malignant Mesothelioma, Stage IV Pleural Mesothelioma
What this study did
NCT01669798 · AA Secord
2013-02 – 2018-02 · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
What this study did
NCT01610869 · University College, London
2014-08 – 2018-01-11 · Ovarian Cancer, Fallopian Tube Cancer
What this study did
NCT01658462 · Centre Oscar Lambret
2013-05 – 2017-10-30 · Breast Cancer
What this study did
NCT02558387 · Samsung Medical Center
2014-11 – 2017-01 · Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck
What this study did
NCT01004003 · Boehringer Ingelheim
2009-10-22 – 2016-10-12 · Carcinoma, Hepatocellular
What this study did
NCT02780700 · Boehringer Ingelheim
2016-07-05 – 2016-09-09 · Colorectal Neoplasms
What this study did
NCT02152059 · AHS Cancer Control Alberta
2014-07 – 2016-07 · Small Cell Lung Cancer, Platinum-sensitive
What this study did
NCT01441297 · Ji-youn Han
2011-12 – 2016-03-31 · Small Cell Lung Cancer, Small Cell Lung Cancer Recurrent
What this study did
NCT02278978 · National Taiwan University Hospital
2014-10 – 2016-03 · Urothelial Carcinoma
What this study did
NCT00987935 · Boehringer Ingelheim
2009-10 – 2016-01 · Carcinoma, Hepatocellular
What this study did
NCT01225887 · Gynecologic Oncology Group
2011-10 – 2016-01 · Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Transitional Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm, Recurrent Uterine Corpus Carcinoma
What this study did
NCT01417156 · Boehringer Ingelheim
2011-09 – 2015-10 · Pulmonary Fibrosis
What this study did
NCT01380782 · Patrick Y. Wen, MD
2012-05 – 2014-07 · Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
What this study did
NCT01251484 · Ulrik Lassen
2011-01 – 2012-08 · Recurrent Glioblastoma
What this study did
NCT00904839 · Boehringer Ingelheim
2009-05 – 2012-01 · Colorectal Neoplasms
What this study did
NCT00801294 · Boehringer Ingelheim
2006-07-01 – 2007-11-01 · Colorectal Neoplasms
What this study did
NCT02182063 · Boehringer Ingelheim
2005-11 – 2007-01 · Prostatic Neoplasms
What this study did
Phase 1/2 (7)
Other / comorbidity
NCT03361319 · Royal Marsden NHS Foundation Trust
2020-07 – 2023-07 · NSCLC, Recurrent, Adenocarcinoma of Lung
What this study did
NCT02902484 · University of Texas Southwestern Medical Center
2017-09-07 – 2021-10-26 · Cancer of Pancreas
What this study did
NCT02393755 · Roswell Park Cancer Institute
2015-05-08 – 2021-05-18 · Colon Adenocarcinoma, Rectal Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
What this study did
NCT02308553 · Prof. Dr. med. Dirk Schadendorf
2015-03-17 – 2019-11 · Cutaneous Malignant Melanoma
What this study did
NCT01666600 · Prof. Dr. Wolfgang Wick
2012-08 – 2017-09 · Glioblastoma Multiforme
What this study did
NCT01488344 · University Hospital Muenster
2012-03 – 2014-11 · Acute Myeloid Leukemia
What this study did
NCT01484080 · Centro Nacional de Investigaciones Oncologicas CARLOS III
2011-10 – 2014-04 · Breast Cancer
What this study did
Phase 1 (48)
Idiopathic Pulmonary Fibrosis
NCT05195918 · Hal Chapman
2023-08-24 – 2026-03-19 · Idiopathic Pulmonary Fibrosis
What this study did
NCT05817240 · Endeavor Biomedicines, Inc.
2023-05-03 – 2023-06-21 · Idiopathic Pulmonary Fibrosis
What this study did
NCT05383131 · Sunshine Lake Pharma Co., Ltd.
2021-06-23 – 2021-11-30 · Idiopathic Pulmonary Fibrosis
What this study did
NCT07588646 · Sunshine Lake Pharma Co., Ltd.
2021-06-29 – 2021-11-30 · Idiopathic Pulmonary Fibrosis
What this study did
NCT04888715 · Daewoong Pharmaceutical Co. LTD.
2021-07-23 – 2021-08-18 · Idiopathic Pulmonary Fibrosis
What this study did
Systemic Sclerosis
NCT03675581 · Boehringer Ingelheim
2018-11-08 – 2019-10-10 · Scleroderma, Systemic
What this study did
Other / comorbidity
NCT03513484 · Northwestern University
2018-11-14 – 2027-01 · Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Fibroblast Growth Factor Basic Form Measurement, FLT3 Internal Tandem Duplication, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT07229716 · Guangdong Hengrui Pharmaceutical Co., Ltd
2026-04-04 – 2026-06-18 · Pulmonary Fibrosis
What this study did
NCT02856425 · Gustave Roussy, Cancer Campus, Grand Paris
2016-11-10 – 2026-01-10 · Patients With Any Advanced Solid Tumors
What this study did
NCT07015398 · Trevi Therapeutics
2025-06-30 – 2025-09-26 · Healthy Participants
What this study did
NCT06717100 · PureTech
2024-12-17 – 2025-03-17 · Drug Interactions
What this study did
NCT06070610 · Boehringer Ingelheim
2023-11-08 – 2023-12-14 · Healthy
What this study did
NCT05644600 · AstraZeneca
2023-05-26 – 2023-07-17 · Healthy Subjects
What this study did
NCT05262751 · Boehringer Ingelheim
2022-03-28 – 2022-11-30 · Healthy
What this study did
NCT04971746 · Lakefront Biotherapeutics NV
2021-07-19 – 2022-05-09 · Healthy
What this study did
NCT04939467 · Blade Therapeutics
2021-10-15 – 2022-04-01 · Drug Drug Interaction
What this study did
NCT04938453 · Boehringer Ingelheim
2021-07-14 – 2021-08-30 · Healthy
What this study did
NCT02835833 · University of Alabama at Birmingham
2016-06-09 – 2018-06-14 · Renal Cell Carcinoma, Colorectal Adenocarcinoma, Non-squamous Non-small Cell Lung Cancer, Platinum-refractory Ovarian Carcinoma, Cervical Carcinoma
What this study did
NCT02619162 · Centro Nacional de Investigaciones Oncologicas CARLOS III
2015-07 – 2018-06 · Breast Cancer
What this study did
NCT02751385 · Boehringer Ingelheim
2016-05-20 – 2017-11-28 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01349296 · University of Cologne
2012-07 – 2016-05 · Solid Tumors
What this study did
NCT01314105 · Boehringer Ingelheim
2011-03-15 – 2016-04-04 · Ovarian Neoplasms, Peritoneal Neoplasms
What this study did
NCT02667704 · Boehringer Ingelheim
2016-02 – 2016-03 · Healthy
What this study did
NCT01684111 · Aktion Bronchialkarzinom e.V.
2013-06 – 2016-01 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01485874 · Hoosier Cancer Research Network
2011-11 – 2015-12 · Ovarian Cancer
What this study did
NCT02572752 · Boehringer Ingelheim
2015-08 – 2015-11 · Healthy
What this study did
NCT02191865 · Boehringer Ingelheim
2014-07 – 2015-01 · Hepatic Insufficiency
What this study did
NCT01594125 · Boehringer Ingelheim
2012-05 – 2015-01 · Carcinoma, Hepatocellular
What this study did
NCT00998296 · Boehringer Ingelheim
2009-10 – 2014-07 · Neoplasms
What this study did
NCT01770392 · Boehringer Ingelheim
2013-01 – 2013-03 · Healthy
What this study did
NCT01022853 · Boehringer Ingelheim
2009-12 – 2013-02 · Neoplasms
What this study did
NCT01679613 · Boehringer Ingelheim
2012-09 – 2012-11 · Healthy
What this study did
NCT01329549 · Boehringer Ingelheim
2011-04 – 2012-10 · Ovarian Neoplasms
What this study did
NCT00730821 · Boehringer Ingelheim
2007-01 – 2009-08 · Neoplasms
What this study did
NCT02182128 · Boehringer Ingelheim
2006-06 – 2009-06 · Tumors
What this study did
NCT02182219 · Boehringer Ingelheim
2005-11-01 – 2007-04-01 · Prostatic Neoplasms
What this study did
NCT02182245 · Boehringer Ingelheim
2005-10-01 – 2007-01-01 · Genital Neoplasms, Female
What this study did
NCT02182154 · Boehringer Ingelheim
2005-10 – 2005-11 · Healthy
What this study did
NCT02182076 · Boehringer Ingelheim
2005-10 – 2005-11 · Healthy
What this study did
NCT02182206 · Boehringer Ingelheim
2003-06 – 2005-06 · Tumors
What this study did
NCT02182141 · Boehringer Ingelheim
2003-04 – 2005-03 · Multiple Myeloma
What this study did
NCT01951846 · Boehringer Ingelheim
2002-11 – 2004-11 · Malignant Solid Tumour
What this study did
Phase 4 (10)
Idiopathic Pulmonary Fibrosis
NCT03939520 · Hospices Civils de Lyon
2020-06-11 – 2026-01-09 · Progressive Idiopathic Pulmonary Fibrosis
What this study did
NCT03717012 · Boehringer Ingelheim
2018-11-15 – 2020-06-10 · Idiopathic Pulmonary Fibrosis
What this study did
NCT02788474 · Boehringer Ingelheim
2016-06-09 – 2018-06-08 · Idiopathic Pulmonary Fibrosis
What this study did
NCT02598193 · Hoffmann-La Roche
2016-01-14 – 2017-05-16 · Idiopathic Pulmonary Fibrosis
What this study did
NCT02606877 · Boehringer Ingelheim
2016-04-19 – 2017-03-22 · Idiopathic Pulmonary Fibrosis
What this study did
NCT02579603 · Boehringer Ingelheim
2015-10-16 – 2017-01-31 · Idiopathic Pulmonary Fibrosis
What this study did
Other / comorbidity
NCT06479603 · Post Graduate Institute of Medical Education and Research, Chandigarh
2024-06-30 – 2026-01-31 · Sarcoidosis, Pulmonary
What this study did
NCT05799755 · Rohit Aggarwal, MD
2023-08-01 – 2025-12-31 · Myositis Associated Interstitial Lund Disease (MA-ILD)
What this study did
NCT04619680 · Icahn School of Medicine at Mount Sinai
2020-11-18 – 2024-03-02 · Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease
What this study did
NCT04856111 · Post Graduate Institute of Medical Education and Research, Chandigarh
2021-03-17 – 2022-11-30 · Novel Coronavirus-induced Lung Fibrosis
What this study did
Early phase / not applicable (3)
Idiopathic Pulmonary Fibrosis
NCT05755308 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2023-10 – 2026-04 · Idiopathic Pulmonary Fibrosis
What this study did
NCT02551068 · University of British Columbia
2015-12 – 2025-08 · Idiopathic Pulmonary Fibrosis
What this study did
Other / comorbidity
NCT05335278 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2021-06-01 – 2025-04-30 · Interstitial Lung Disease, Myopathy, Inflammatory
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (2)
Idiopathic Pulmonary Fibrosis
NCT07933133 · CSPC-NBP Pharmaceutical Co., Ltd.
2026-12-01 – 2030-02-01 · Idiopathic Pulmonary Fibrosis
What this study did
NCT01890265 · Kyntra Bio
2013-07-30 – 2017-11-16 · Idiopathic Pulmonary Fibrosis
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 1 (1)
Idiopathic Pulmonary Fibrosis
NCT07454291 · Endeavor Biomedicines, Inc.
2026-04-28 – 2026-10 · Idiopathic Pulmonary Fibrosis
What this study did

Competitive landscape

Other Triple angiokinase inhibitor (VEGFR/FGFR/PDGFR) drugs

Nintedanib (Vargatef). Compare all 2 Triple angiokinase inhibitor (VEGFR/FGFR/PDGFR) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Idiopathic Pulmonary Fibrosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nintedanib (Ofev): this drugApprovedSmall moleculeTriple angiokinase inhibitor (VEGFR/FGFR/PDGFR)Partial signal
NCT01335464: INPULSIS-1, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=309) vs placebo (n=204): -114.65 vs -239.91 mL/year; difference 125.26 mL/year (95% CI 77.68 to 172.84), p < 0.0001 (CT.gov posted results).
NCT01335477: INPULSIS-2, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=329) vs placebo (n=219): -113.59 vs -207.32 mL/year; difference 93.73 mL/year (95% CI 44.78 to 142.68), p = 0.0002 (CT.gov posted results).
Nerandomilast (Jascayd)ApprovedSmall moleculePDE4BReliable signal
NCT05321069: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52): Placebo -183.48 Milliliters (mL) (95% CI -210.86 to -156.1) | Nerandomilast 9 mg BID -138.6 Milliliters (mL) (95% CI -165.59 to -111.61) | Nerandomilast 18 mg BID -114.65 Milliliters (mL) (95% CI -141.81 to -87.5)
NCT04419506: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks (Baseline (day 1) and week 12.): Placebo - Antifibrotics at Baseline -77.7 Milliliter (95% CI -124.87 to -30.53) | BI 1015550 - Antifibrotics at Baseline 2.72 Milliliter (95% CI -33.46 to 38.89) | Placebo - Non-antifibrotics at Baseline -95.62 Milliliter (95% CI -157.13 to -34.1) | BI 1015550 - Non-antifibrotics at Baseline 6.1 Milliliter (95% CI -39.67 to 51.88)
Pirfenidone (Esbriet)ApprovedSmall moleculePyridoneReliable signal
NCT01366209: At week 52, decline in percent predicted FVC of 10 points or more, or death: pirfenidone 16.5% vs placebo 31.8% (relative reduction 47.9%); no FVC decline 22.7% vs 9.7%; P<0.001 (ASCEND, NEJM 2014; CT.gov posted results).
Treprostinil (Tyvaso DPI)
Approved(overall)
Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
HSK44459Phase 3Small moleculePDE4Bnot yet gradedNo reviewed efficacy summary in this indication
Nintedanib (Vargatef)
Phase 3(overall)
Small moleculeTriple angiokinase inhibitor (VEGFR/FGFR/PDGFR)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Treprostinil (Tyvaso)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
ABBV-722
Phase 1(overall)
Small moleculeLPAR1not yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
PamrevlumabDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication
Voxelotor (Oxbryta)DiscontinuedSmall moleculeHemoglobin S (HbS)not yet gradedNo reviewed efficacy summary in this indication
ZiritaxestatDiscontinuedSmall moleculeautotaxin (ENPP2)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Nintedanib (Ofev) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Telangiectasia, Hereditary HemorrhagicRecruiting
Est. primary completion 2026-12 · NCT04976036 · CT.gov ↗
What to watch
2027 (2)
March 2027 (1)
Phase 2Idiopathic Pulmonary FibrosisNot yet recruiting
Est. primary completion 2027-03-01 · NCT07583589 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3Systemic SclerosisRecruiting
Est. primary completion 2027-12-30 · NCT06297096 · CT.gov ↗
What to watch
2028 (1)
November 2028 (1)
Phase 3Systemic SclerosisNot yet recruiting
Est. primary completion 2028-11-14 · NCT07335562 · CT.gov ↗
What to watch
2030 (1)
May 2030 (1)
Phase 2Castleman DiseaseNot yet recruiting
Est. primary completion 2030-05-01 · NCT06643091 · CT.gov ↗
What to watch

See the full readout calendar ↗